Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 19Active not recruiting 8Not yet recruiting 2Completed 2No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × talquetamab × Clear all
NCT03601078 2026-03-04

KarMMa-2

Celgene

Phase 2 Completed
312 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT04773522 2025-10-01

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Janssen Pharmaceutical K.K.

Phase 1 Completed
15 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡